Pharmaceutical Stocks - Directory w/ AI Reviews
Pharmaceutical companies develop, manufacture, and market the drugs that treat disease and extend life — one of the most research-intensive and regulated industries in the global economy. Eli Lilly and Novo Nordisk have seen explosive growth driven by their GLP-1 weight loss and diabetes drugs, while AbbVie's immunology franchise anchored by Humira generates billions in annual revenue. Merck, AstraZeneca, and Gilead Sciences each maintain diverse oncology and specialty drug pipelines that drive long-term earnings visibility.
1
4.8
New
Eli Lilly
LLY
$1,040.00
+0.17%
P/E: 54.7
Eli Lilly is a dominant pharmaceutical stock riding the unprecedented commercial success of its GLP-1 therapies Mounjaro and Zepbound, which have positioned the company at the forefront of the obesity treatment revolution and made it one of the most highly valued pharma companies in history.
2
4.6
New
Merck
MRK
$121.41
+1.82%
P/E: 14.9
Merck is one of the world's most important pharmaceutical stocks, anchored by Keytruda—the best-selling cancer drug globally—with a deep pipeline in oncology, vaccines, and cardiometabolic disease.
3
4.6
New
Vertex Pharmaceuticals
VRTX
$491.47
+5.69%
P/E: 35.0
Vertex is the dominant pharmaceutical company in cystic fibrosis treatment, with its Trikafta franchise representing the standard of care and generating billions in highly profitable revenue with limited direct competition.
4
4.5
New
Novo Nordisk
NVO
$49.57
+1.31%
P/E: 2.9
Novo Nordisk is a pharmaceutical stock powerhouse and the undisputed global leader in GLP-1 therapies, with Ozempic and Wegovy generating explosive revenue growth that has made it Europe's most valuable company and a must-watch holding for pharmaceutical sector investors.
5
4.5
New
AbbVie
ABBV
$231.50
+1.76%
P/E: 25.3
AbbVie is a leading pharmaceutical stock with blockbuster immunology drugs Skyrizi and Rinvoq replacing Humira revenue, alongside strong franchises in oncology, aesthetics, and neuroscience.
6
4.4
New
AstraZeneca
AZN
$205.55
+0.50%
P/E: 34.6
AstraZeneca is a global pharmaceutical leader with a strong pipeline in oncology, cardiovascular, and respiratory therapies, consistently delivering above-industry revenue growth.
7
4.4
New
Gilead Sciences
GILD
$154.98
+2.09%
P/E: 17.8
Gilead Sciences is a major pharmaceutical company with a dominant franchise in HIV treatment and prevention, generating billions in annual revenue from its market-leading antiretroviral therapies including Biktarvy.
8
3.9
New
Bristol-Myers Squibb
BMY
$60.74
+1.47%
P/E: 28.7
Bristol-Myers Squibb is a top-tier global pharmaceutical company with a diverse portfolio of blockbuster drugs spanning oncology, cardiovascular, immunology, and fibrosis, generating tens of billions in annual revenue.
9
3.8
New
Pfizer
PFE
$27.58
+0.40%
P/E: 8.5
Pfizer is a major pharmaceutical stock undergoing a strategic transformation, pivoting from its COVID-19 windfall toward becoming an oncology leader through the Seagen acquisition, while offering investors an attractive dividend yield and a deeply discounted valuation relative to its large-cap pharm
10
3.2
New
Viatris
VTRS
Viatris is a global healthcare company formed from the Pfizer-Mylan merger, producing a broad portfolio of generic drugs, branded medicines, and biosimilars across diverse therapeutic areas.
11
2.6
New
Bayer AG
BAYRY
Bayer is a German life sciences giant with major positions in crop science, pharmaceuticals, and consumer health, though ongoing Monsanto-related litigation remains a key investor concern.